Malignant mixed Mullerian tumor

Search Trials
Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
Status:
Completed
Last Changed:
Sep 5, 2016
First Changed:
Jan 1, 1970
Disease(s):
Mixed Tumor, Mullerian
Intervention(s):
CarboplatinPaclitaxel
Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
Status:
Completed
Last Changed:
Jul 8, 2012
First Changed:
Feb 6, 2008
Disease(s):
Uterine Carcinosarcoma
Intervention(s):
paclitaxelcarboplatinBSI-201 (Iniparib)
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Status:
Recruiting
Last Changed:
Jan 1, 1970
First Changed:
Feb 7, 2017
Disease(s):
Carcinosarcoma, Ovarian
Intervention(s):
GalunisertibPaclitaxelCarboplatin
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Status:
Not yet recruiting
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Ovarian Cancer
Intervention(s):
PaclitaxelTAK228
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Status:
Not yet recruiting
Last Changed:
Jan 1, 1970
First Changed:
Jan 1, 1970
Disease(s):
Ovarian Carcinosarcoma
Intervention(s):
NiraparibNiraparib plus TSR-042Chemotherapy Drugs

Connect. Empower. Inspire.